Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Human T-lymphotropic virus 2

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44341   clinical trials with a EudraCT protocol, of which   7370   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    211 result(s) found for: Human T-lymphotropic virus 2. Displaying page 5 of 11.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2008-006644-19 Sponsor Protocol Number: CRISTAL Start Date*: 2009-01-29
    Sponsor Name:AZIENDA OSPEDALIERA SAN GERARDO DI MONZA
    Full Title: Evaluation of inflammatory immune parameters predicting cardiovascular risk in HIV-1-infected antiretroviral therapy naive patients treated with atazanavir/ritonavir versus lopinavir/ritonavir base...
    Medical condition: HIV infection
    Disease: Version SOC Term Classification Code Term Level
    9.1 10020161 HIV infection LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-011171-76 Sponsor Protocol Number: ANRS 145 Start Date*: 2009-05-25
    Sponsor Name:Agence nationale de recherches sur le sida et les hépatites virales. ANRS.
    Full Title: Etude pilote évaluant l’intérêt d’une intensification par maraviroc (Celsentri®) chez des patients infectés par le VIH-1 présentant une restauration immunitaire insuffisante malgré une charge viral...
    Medical condition: Infection VIH
    Disease: Version SOC Term Classification Code Term Level
    11.1 10020161 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2015-004195-30 Sponsor Protocol Number: ABX464-004 Start Date*: 2016-05-24
    Sponsor Name:Abivax
    Full Title: A multi-center, randomized, double-blind, placebo-controlled Phase IIa trial to compare the safety of ABX464 given at a fixed dose to placebo in fully controlled HIV infected patients treated with ...
    Medical condition: Human Immunodeficiency Virus (HIV)
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004862 10020443 Human immunodeficiency virus syndrome LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed) ES (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2007-006302-13 Sponsor Protocol Number: CT-BI Vacc-4x 2007/1 Start Date*: 2008-06-04
    Sponsor Name:Bionor Immuno AS
    Full Title: A Phase II, Randomized, Double-Blind, Multicenter, Immunogenicity Study of Vacc-4x Versus Placebo in Patients Infected with HIV-1 Who Have Maintained an Adequate Response to ART
    Medical condition: HIV positive subjects who have been clinically stable on antiretroviral therapy for the last six months with a viral load less than 50 copies/mL for the last six months and a CD4 cell count => 400 ...
    Disease: Version SOC Term Classification Code Term Level
    12.0 10020161 HIV infection LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed) ES (Completed) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-002208-15 Sponsor Protocol Number: 208132 Start Date*: 2019-03-04
    Sponsor Name:ViiV Healthcare UK Limited
    Full Title: A Randomized, Double-Blind (Sponsor-unblinded), Placebo-Controlled, Adaptive Trial to Investigate the Antiviral Effect, Safety, Tolerability and Pharmacokinetics of GSK3640254 in HIV-1 Infected Tre...
    Medical condition: Treatment of human immunodeficiency virus-1 (HIV-1)
    Disease: Version SOC Term Classification Code Term Level
    20.1 10021881 - Infections and infestations 10020161 HIV infection PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2008-005113-21 Sponsor Protocol Number: RDEA806-202 Start Date*: 2008-11-20
    Sponsor Name:Ardea Biosciences, Inc.
    Full Title: A Multicenter, Randomized, Double-Blind, Phase 2b Trial to Determine The Efficacy, Tolerability And Safety Of 3 Dose Regimens Of RDEA806 and Open-Label Efavirenz as Active Control in HIV 1-Infected...
    Medical condition: HIV infection
    Disease: Version SOC Term Classification Code Term Level
    9.1 10020161 HIV infection LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) DE (Prematurely Ended) PL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2009-016361-28 Sponsor Protocol Number: AI424397 Start Date*: 2011-01-26
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Prospective Single Arm, Open-label, International, Multicenter Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Atazanavir (ATV) Powder Boosted with Ritonavir (RTV) Liquid with an O...
    Medical condition: HIV, PEDIATRIC
    Disease: Version SOC Term Classification Code Term Level
    9.1 10020161 HIV infection LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: PL (Completed) IT (Prematurely Ended) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2014-004819-37 Sponsor Protocol Number: APART_2014 Start Date*: 2015-04-16
    Sponsor Name:University College Dublin
    Full Title: A multi-centre, prospective, randomised trial of short course alendronate therapy or placebo combined with vitamin D and calcium to prevent loss of bone mineral density in antiretroviral-naïve, HIV...
    Medical condition: Human immunodeficiency virus (HIV) infection
    Disease: Version SOC Term Classification Code Term Level
    17.1 10021881 - Infections and infestations 10020161 HIV infection PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Completed) DK (Prematurely Ended) GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2004-001246-33 Sponsor Protocol Number: TMC114-C208 Start Date*: 2004-11-23
    Sponsor Name:Tibotec Pharmaceuticals Limited Ireland
    Full Title: An open label trial of TMC114/RTV in HIV-1 infected subjects who were randomized in the trials TMC114-C201, TMC114-C207 or in sponsor selected Phase I trials.
    Medical condition: HIV-1 infection
    Disease: Version SOC Term Classification Code Term Level
    9.1 10020161 HIV infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) GB (Completed) IT (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2004-004055-19 Sponsor Protocol Number: TMC278-C204 Start Date*: 2005-08-03
    Sponsor Name:Tibotec Pharmaceuticals
    Full Title: A Phase IIb randomized, partially blinded, dose-finding trial of TMC278 in antiretroviral naive HIV-1 infected subjects.
    Medical condition: HIV infection
    Disease: Version SOC Term Classification Code Term Level
    12.1 10020161 HIV infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2008-007038-24 Sponsor Protocol Number: A4001078 Start Date*: 2009-06-12
    Sponsor Name:ViiV Healthcare UK Limited
    Full Title: PILOT STUDY OF NOVEL COMBINATION OF MARAVIROC + ATAZANAVIR/RITONAVIR VS ATAZANAVIR/RITONAVIR + EMTRICITABINE/TENOFOVIR FOR THE TREATMENT OF TREATMENT NAÏVE HIV-INFECTED PATIENTS WITH R5 HIV-1
    Medical condition: TREATMENT OF TREATMENT NAÏVE HIV-INFECTED PATIENTS WITH R5 HIV-1
    Disease: Version SOC Term Classification Code Term Level
    9.1 10020161 HIV infection LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Completed) GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-005854-21 Sponsor Protocol Number: RDEA806-201 Start Date*: 2008-01-15
    Sponsor Name:Ardea Biosciences Inc.
    Full Title: A multicenter Phase 2a, randomized, double-blind, placebo-controlled, proof-of-concept trial to determine the antiviral activity, pharmacokinetics, tolerability and safety of RDEA806 in HIV-1 posit...
    Medical condition: HIV-1
    Disease: Version SOC Term Classification Code Term Level
    9.1 10020161 HIV infection LLT
    Population Age: Adults Gender: Male
    Trial protocol: DE (Completed) GB (Completed) AT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-006437-40 Sponsor Protocol Number: TMC114HIV3006 Start Date*: 2007-02-05
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A randomised, controlled, opel-label trial to compare the efficacy, safety and tolerability of a treatment simplification by darunavir/ritonavir (DRV/r) 800/100 mg O.D. versus a triple combination ...
    Medical condition: HIV-1
    Disease: Version SOC Term Classification Code Term Level
    8.1 10020161 HIV infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) GB (Completed) HU (Completed) DK (Completed) DE (Completed) PT (Completed) ES (Completed) AT (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2013-001939-47 Sponsor Protocol Number: MK-0518-292 Start Date*: 2014-05-16
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Phase III Multicenter, Double-Blind, Randomized, Active Comparator-Controlled Clinical Trial to Evaluate the Safety and Efficacy of Reformulated Raltegravir 1200 mg Once Daily Versus Raltegravir...
    Medical condition: human immunodeficiency virus infection
    Disease: Version SOC Term Classification Code Term Level
    16.1 10021881 - Infections and infestations 10020161 HIV infection PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed) ES (Completed) PT (Completed) BE (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2007-000783-25 Sponsor Protocol Number: 0518-032 Start Date*: 2007-05-23
    Sponsor Name:Merck Sharp & Dohme de España, S.A.
    Full Title: A Multicenter, Double-Blind, Randomized, Active-Controlled Study to Evaluate the Safety and Antiretroviral Activity of MK-0518 Versus KALETRA™ in HIV-Infected Patients Switched from a Stable KALE...
    Medical condition: HIV Infection
    Disease: Version SOC Term Classification Code Term Level
    9.1 10020161 HIV infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended) DE (Prematurely Ended) GB (Prematurely Ended) DK (Prematurely Ended) IT (Prematurely Ended) PT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2005-000594-22 Sponsor Protocol Number: TMC114-C214 Start Date*: 2005-06-13
    Sponsor Name:Tibotec Pharmaceuticals Limited
    Full Title: A randomized, controlled, open-label trial to compare the efficacy, safety and tolerability of TMC114/RTV versus LPV/RTV in treatment-experienced HIV-1 infected subjects.
    Medical condition: HIV-1 infection
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) AT (Completed) GB (Completed) DE (Completed) DK (Completed) BE (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2007-004392-19 Sponsor Protocol Number: A5271022 Start Date*: 2009-05-20
    Sponsor Name:Pfizer Inc, 235 East 42nd Street, New York, NY 10017
    Full Title: A PHASE 2B MULTICENTER, RANDOMIZED, COMPARATIVE TRIAL OF UK-453,061 VERSUS ETRAVIRINE IN COMBINATION WITH DARUNAVIR/RITONAVIR AND A NUCLEOTIDE/NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR FOR THE TRE...
    Medical condition: HIV-1 Infection
    Disease: Version SOC Term Classification Code Term Level
    9.1 10020161 HIV infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) GB (Completed) ES (Prematurely Ended) PT (Prematurely Ended) IT (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2005-004330-40 Sponsor Protocol Number: 1100.1470 Start Date*: 2006-09-13
    Sponsor Name:Boehringer Ingelheim Pharma GmbH & Co. KG
    Full Title: Open-label, randomised clinical trial to compare the virological efficacy and safety of Atazanavir/Ritonavir on a background of Tenofovir and Emtricitabine vs. Nevirapine on same background, in HIV...
    Medical condition: This randomised, controlled, open-label trial will be conducted in HIV-1-infected patients who have received no previous antiretroviral treatment (of more than 7 days in total).
    Disease: Version SOC Term Classification Code Term Level
    8.1 10020161 HIV infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) PT (Completed) IT (Completed) GB (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2008-002733-70 Sponsor Protocol Number: 0518-071-01 Start Date*: 2008-10-30
    Sponsor Name:Merck & Co., Inc.
    Full Title: "Ensayo clínico en fase III multicéntrico, doble ciego, aleatorizado y con control activo para evaluar la seguridad y la eficacia de raltegravir (MK-0518) administrado una vez al día frente a ralte...
    Medical condition: infección VIH HIV infection
    Disease: Version SOC Term Classification Code Term Level
    11 10020161 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended) GB (Prematurely Ended) DK (Prematurely Ended) FR (Completed) PT (Prematurely Ended) DE (Prematurely Ended) IT (Prematurely Ended) NL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-003654-29 Sponsor Protocol Number: 1100.1486 Start Date*: 2007-11-08
    Sponsor Name:Boehringer Ingelheim Pharma GmbH & Co. KG
    Full Title: A randomised, double blind, double dummy, parallel group, active controlled trial to evaluate the antiviral efficacy of 400 mg QD nevirapine extended release formulation in comparison to 200 mg B...
    Medical condition: HIV-1 infection
    Disease: Version SOC Term Classification Code Term Level
    14.0 10021881 - Infections and infestations 10020160 HIV disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) IE (Completed) PT (Completed) GB (Completed) FR (Completed) IT (Completed) BE (Completed) ES (Completed) NL (Completed) PL (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri Jun 13 00:02:41 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA